Latest Advances

  • Journal: Cells
  • Published —
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.
  • Condition: Non-Small Cell Lung Cancer
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Atezolizumab
  • Number of Patients: 619
  • Published —
The study researched the use of atezolizumab in treating non-small cell lung cancer.
  • Condition: Advanced Epidermal Growth Factor Receptor Mutation Positive Non-Squamous Non-Small Cell Lung Cancer
  • Journal: The Cochrane database of systematic reviews
  • Treatment Used: Chemotherapy
  • Number of Patients: 3023
  • Published —
The study researched the use of chemotherapy in patients with advanced epidermal growth factor receptor mutation positive non-squamous non-small cell lung cancer.
  • Condition: Primary Pulmonary Lymphoepithelioma-Like Carcinoma (PPLELC)
  • Journal: Medicine
  • Treatment Used: Neoadjuvant Treatment
  • Number of Patients: 1
  • Published —
This case report describes a 46-year-old male diagnosed with primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) treated with Sintilimab combined with gemcitabine plus nedaplatin chemotherapy (GP) regimen, supplemented with antiemetics and stomach protection drugs.
  • Condition: Non-Small Cell Lung Cancer (NSCLC)
  • Journal: Scientific reports
  • Treatment Used: Curative and Palliative Radiation Therapy
  • Number of Patients: 50
  • Published —
This review of the literature evaluated and compared the toxicity rates of curative and palliative radiotherapy with and without chemotherapy in patients with non-small cell lung cancer (NSCLC).
  • Condition: EGFR-TKI-Resistant Advanced Non-Small Cell Lung Cancer
  • Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • Treatment Used: Osimertinib
  • Number of Patients: 84
  • Published —
The aim of this study was to explore the effectiveness and safety of Osimertinib in the treatment of patients with first-generation EGFR-TKI-resistant advanced non-small cell lung cancer (NSCLC).
  • Condition: Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Journal: Current oncology (Toronto, Ont.)
  • Treatment Used: Systemic Treatment
  • Number of Patients: 1084
  • Published —
This study explored systemic therapy uptake and survival in patients with advanced non-small lung cancer (NSCLC).
  • Condition: Non-small Cell Lung Cancer
  • Journal: Medicine
  • Treatment Used: Afatinib and Bevacizumab
  • Number of Patients: 1
  • Published —
In this study, researchers evaluated the outcomes of using afatinib and bevacizumab for the treatment of a EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification.
  • Condition: Non-Small Cell Lung Cancer
  • Journal: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • Treatment Used: Adjuvant Chemotherapy
  • Number of Patients: 231
  • Published —
This study aimed to evaluate the effectiveness, safety, and feasibility of adjuvant chemotherapy (AC) for non-small cell lung cancer (NSCLC) patients.
  • Condition: Oligometastatic Disease in Patients with Non-Small Cell Lung Cancer
  • Journal: European respiratory review : an official journal of the European Respiratory Society
  • Treatment Used: Surgery and Radiotherapy, Local Therapy Combined with Systemic Therapy
  • Number of Patients: 0
  • Published —
This review summarized the current treatments for oligometastatic disease in patients with non-small cell lung cancer.
  • Condition: Malignant Tumors
  • Journal: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • Treatment Used: Standardised Treatments Combined with Ubenimex
  • Number of Patients: 1372
  • Published —
The study researched the outcomes of standardized treatments combined with ubenimex for treating malignant tumors.
  • Condition: Stage IV Large Cell Neuroendocrine Carcinoma of the Lung.
  • Journal: Asian Pacific journal of cancer prevention : APJCP
  • Treatment Used: Immunotherapy
  • Number of Patients: 37
  • Published —
This study defined the role of immunotherapy in the treatment of patients with large cell neuroendocrine carcinoma (LCNEC).
Showing 1-12 of 1097